- Previous Close
4,817.90 - Open
4,760.50 - Bid --
- Ask --
- Day's Range
4,753.40 - 4,949.00 - 52 Week Range
4,217.45 - 7,196.85 - Volume
30,004 - Avg. Volume
35,516 - Market Cap (intraday)
221.863B - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
42.66 - EPS (TTM)
115.63 - Earnings Date May 21, 2025 - May 26, 2025
- Forward Dividend & Yield 125.00 (2.59%)
- Ex-Dividend Date Nov 28, 2024
- 1y Target Est
5,465.71
Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes hybrid seeds, such as corn and paddy. Further, it provides digital farming products comprising FarmRise and other digital applications, such as drones for spray services, etc., as well as provides various technologies, such as remote sensing, IoT sensors, GPS, artificial intelligence, and data analytics to monitor and manage crop growth, soil quality, weather patterns, and other factors. The company also exports its products. Bayer CropScience Limited was founded in 1863 and is based in Thane, India.
www.bayer.in1,317
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: BAYERCROP.NS
View MorePerformance Overview: BAYERCROP.NS
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BAYERCROP.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BAYERCROP.NS
View MoreValuation Measures
Market Cap
216.71B
Enterprise Value
207.15B
Trailing P/E
41.58
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.33
Price/Book (mrq)
7.03
Enterprise Value/Revenue
4.14
Enterprise Value/EBITDA
28.47
Financial Highlights
Profitability and Income Statement
Profit Margin
9.98%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
52.17B
Net Income Avi to Common (ttm)
5.21B
Diluted EPS (ttm)
115.63
Balance Sheet and Cash Flow
Total Cash (mrq)
9.8B
Total Debt/Equity (mrq)
1.08%
Levered Free Cash Flow (ttm)
--